Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Review
  • Published:

The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features

Leukemia volume 22, pages 1308–1319 (2008)Cite this article

Abstract

The 2001 World Health Organization (WHO)-sponsored classification of hematopoietic tumors has, for the first time, clearly defined a group of rare myeloid neoplasms termed myelodysplastic/myeloproliferative diseases (MDS/MPDs). This group includes three main entities, chronic myelomonocytic leukemia, atypical chronic myeloid leukemia and juvenile myelomonocytic leukemia, and also several less well defined, ‘unclassifiable’ disorders with MDS/MPN-like features. In the upcoming fourth edition of the WHO fascicle, due out later this year, the term ‘MPD’ is replaced by ‘myeloproliferative neoplasm (MPN)’. Accordingly, the term MDS/MPD is being replaced by ‘MDS/MPN’ that will be used in this review. Although much progress has been made in understanding the molecular pathogenesis of myeloid neoplasms, most of the diseases included in the group of MDS/MPN still remain ‘clinicopathologically assigned’. In other words, they can only be accurately categorized by a careful multiparametric approach that is based on the integration of bone marrow and peripheral blood morphology with other laboratory and clinical findings. The current ‘spotlight’ review provides practical guidelines, which should allow for a reproducible classification of these uncommon neoplasms when encountered in clinical practice.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Niemeyer CM, Kratz CP, Hasle H . Pediatric myelodysplastic syndromes. Curr Treat Options Oncol 2005; 6: 209–214.

    Article  PubMed  Google Scholar 

  2. Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP . Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD and MDS-derived AML. Blood 2008; 111: 1534–1542.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Mohamedali A, Gäken J, Twine NA, Ingram W, Westwood N, Lea NC et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007; 110: 3365–3373. E-pub 18 July 2007.

    Article  CAS  PubMed  Google Scholar 

  4. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the acute leukemias. Br J Haematol 1976; 33: 451–458.

    Article  CAS  PubMed  Google Scholar 

  5. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199.

    Article  CAS  PubMed  Google Scholar 

  6. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick H et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French–American–British Cooperative Leukaemia Group. Br J Haematol 1994; 87: 746–754.

    Article  CAS  PubMed  Google Scholar 

  7. Vardiman JW . Myelodysplastic/myeloproliferative diseases: introduction. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumors: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001, pp 47–48.

    Google Scholar 

  8. Tefferi A, Elliott MA, Pardanani A . Atypical myeloproliferative disorders: diagnosis and management. Mayo Clin Proc 2006; 81: 553–563.

    Article  CAS  PubMed  Google Scholar 

  9. Oscier D . Atypical chronic myeloid leukemias. Pathol Biol (Paris) 1997; 45: 587–593.

    CAS  Google Scholar 

  10. Vardiman JW, Imbert M, Pierre R, Bain B, Brunning RD, Flandrin G . Atypical chronic myeloid leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumors: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001, pp 53–54.

    Google Scholar 

  11. Breccia M, Biondo F, Latagliata R, Carmosino I, Mandelli F, Alimena G . Identification of risk factors in atypical chronic myeloid leukemia. Haematologica 2006; 91: 1566–1568. E-pub 17 October 2006.

    PubMed  Google Scholar 

  12. Orazi A, O'Malley DP, Arber D . Illustrated Pathology of the Bone Marrow. Cambridge University Press: Cambridge, UK, 2006, pp 88–92.

    Book  Google Scholar 

  13. McClure RF, Dewald GW, Hoyer JD, Hanson CA . Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course. Br J Haematol 1999; 106: 445–454.

    Article  CAS  PubMed  Google Scholar 

  14. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162–2168. E-pub 26 May 2005.

    Article  CAS  PubMed  Google Scholar 

  15. Falko F, Horn T, Koch I, Vela T, Orazi A . Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative myeloid neoplasm. Leuk Res 2008; in press.

  16. Bousquet M, Quelen C, De Mas V, Duchayne E, Roquefeuil B, Delsol G et al. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 2005; 24: 7248–7252.

    Article  CAS  PubMed  Google Scholar 

  17. Felman P, Bryon PA, Gentilhomme O, Ffrench M, Charrin C, Espinouse D et al. The syndrome of abnormal chromatin clumping in leucocytes: a myelodysplastic disorder with proliferative features? Br J Haematol 1988; 70: 49–54.

    Article  CAS  PubMed  Google Scholar 

  18. Invernizzi R, Custodi P, de Fazio P, Bergamaschi G, Fenoglio C, Ricevuti G et al. The syndrome of abnormal chromatin clumping in leucocytes: clinical and biological study of a case. Haematologica 1990; 75: 532–536.

    CAS  PubMed  Google Scholar 

  19. Tertian G, Misrahi M, Diallo D, Mielot F . Abnormal chromatin clumping in granulocytes in a case of Ph1-negative, BCR-ABL rearrangement positive, haematologically atypical chronic myeloid leukaemia (CML). Nouv Rev Fr Hematol 1995; 37: 245.

    CAS  PubMed  Google Scholar 

  20. Carulli G, Fabiani O, Azzarà A . The syndrome of abnormal chromatin clumping in leukocytes. Haematologica 1997; 82: 635–636.

    CAS  PubMed  Google Scholar 

  21. Vardiman JW, Imbert M, Pierre R, Brunning RD, Bain B, Flandrin G et al. Chronic myelomonocytic leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumors: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001, pp 49–52.

    Google Scholar 

  22. Orazi A, Chiu R, O'Malley DP, Czader M, Allen SL, An C et al. Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistology. Mod Pathol 2006; 19: 1536–1545.

    Article  CAS  PubMed  Google Scholar 

  23. Germing U, Gattermann N, Minning H, Heyll A, Aul C . Problems in the classification of CMML-dysplastic versus proliferative type. Leuk Res 1998; 22: 871–878.

    Article  CAS  PubMed  Google Scholar 

  24. Fenaux P, Beuscart R, Lai JL, Jouet JP, Bauters F . Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol 1988; 6: 1417–1424.

    Article  CAS  PubMed  Google Scholar 

  25. Storniolo AM, Moloney WC, Rosenthal DS, Cox C, Bennett JM . Chronic myelomonocytic leukemia. Leukemia 1990; 4: 766–770.

    CAS  PubMed  Google Scholar 

  26. Lacronique-Gazaille C, Chaury MP, Le Guyader A, Faucher JL, Bordessoule D, Feuillard J . A simple method for detection of major phenotypic abnormalities in myelodysplastic syndromes: expression of CD56 in CMML. Haematologica 2007; 92: 859–860.

    Article  PubMed  Google Scholar 

  27. Xu Y, McKenna RW, Karandikar NJ, Pildain AJ, Kroft SH . Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am J Clin Pathol 2005; 124: 799–806.

    Article  PubMed  Google Scholar 

  28. Germing U, Strupp C, Knipp S, Kuendgen A, Giagounidis A, Hildebrandt B et al. Chronic myelomonocytic leukemia in the light of the WHO proposals. Haematologica 2007; 92: 974–977.

    Article  PubMed  Google Scholar 

  29. Chen YC, Chou JM, Letendre L, Li CY . Clinical importance of bone marrow monocytic nodules in patients with myelodysplasia: retrospective analysis of 21 cases. Am J Hematol 2005; 79: 329–331.

    Article  PubMed  Google Scholar 

  30. Vermi W, Facchetti F, Rosati S, Vergoni F, Rossi E, Festa S et al. Nodal and extranodal tumor-forming accumulation of plasmacytoid monocytes/interferon-producing cells associated with myeloid disorders. Am J Surg Pathol 2004; 28: 585–595.

    Article  PubMed  Google Scholar 

  31. Facchetti F, de Wolf-Peeters C, Mason DY, Pulford K, van den Oord JJ, Desmet VJ . Plasmacytoid T cells. Immunohistochemical evidence for their monocyte/macrophage origin. Am J Pathol 1988; 133: 15–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. O'Malley DP, Kim YS, Perkins SL, Baldridge L, Juliar BE, Orazi A . Morphologic and immunohistochemical evaluation of splenic hematopoietic proliferations in neoplastic and benign disorders. Mod Pathol 2005; 18: 1550–1561.

    Article  CAS  PubMed  Google Scholar 

  33. Steensma DP, Tefferi A, Li CY . Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome. Leuk Res 2003; 27: 775–782.

    Article  PubMed  Google Scholar 

  34. Porcu P, Neiman RS, Orazi A . Splenectomy in agnogenic myeloid metaplasia. Blood 1999; 93: 2132–2134.

    CAS  PubMed  Google Scholar 

  35. Koo CH, Mason DY, Miller R, Ben-Ezra J, Sheibani K, Rappaport H . Additional evidence that ‘plasmacytoid T-cell lymphoma’ associated with chronic myeloproliferative disorders is of macrophage/monocyte origin. Am J Clin Pathol 1990; 93: 822–827.

    Article  CAS  PubMed  Google Scholar 

  36. Baddoura FK, Hanson C, Chan WC . Plasmacytoid monocyte proliferation associated with myeloproliferative disorders. Cancer 1992; 69: 1457–1467.

    Article  CAS  PubMed  Google Scholar 

  37. Tefferi A, Gilliland G . Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system. Best Pract Res Clin Haematol 2006; 19: 365–385.

    Article  CAS  PubMed  Google Scholar 

  38. Drechsler M, Hildebrandt B, Kündgen A, Germing U, Royer-Pokora B . Fusion of H4/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib. Ann Hematol 2007; 86: 353–354.

    Article  PubMed  Google Scholar 

  39. Melo JV, Myint H, Galton DA, Goldman JM . P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia 1994; 8: 208–211.

    CAS  PubMed  Google Scholar 

  40. Ohsaka A, Shiina S, Kobayashi M, Kudo H, Kawaguchi R . Philadelphia chromosome-positive chronic myeloid leukemia expressing p190(BCR-ABL). Intern Med 2002; 41: 1183–1187. Review.

    Article  PubMed  Google Scholar 

  41. Hirsch-Ginsberg C, LeMaistre AC, Kantarjian H, Talpaz M, Cork A, Freireich EJ et al. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood 1990; 76: 1214–1219.

    CAS  PubMed  Google Scholar 

  42. Tefferi A, Gilliland DG . Oncogenes in myeloproliferative disorders. Cell Cycle 2007; 6: 550–566. E-pub 24 March 2007 Review.

    Article  CAS  PubMed  Google Scholar 

  43. Loh ML, Martinelli S, Cordeddu V, Reynolds MG, Vattikuti S, Lee CM et al. Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Res 2005; 29: 459–462.

    Article  CAS  PubMed  Google Scholar 

  44. Kurzrock R, Bueso-Ramos CE, Kantarjian H, Freireich E, Tucker SL, Siciliano M et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol 2001; 19: 2915–2926.

    Article  CAS  PubMed  Google Scholar 

  45. Onida F, Ball G, Kantarjian HM, Smith TL, Glassman A, Albitar M et al. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer 2002; 95: 1673–1684.

    Article  PubMed  Google Scholar 

  46. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.

    CAS  PubMed  Google Scholar 

  47. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W . Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992; 6: 52–59.

    CAS  PubMed  Google Scholar 

  48. González-Medina I, Bueno J, Torrequebrada A, López A, Vallespí T, Massagué I . Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. Leuk Res 2002; 26: 821–824.

    Article  PubMed  Google Scholar 

  49. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840–849.

    Article  CAS  PubMed  Google Scholar 

  50. Germing U, Kündgen A, Gattermann N . Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 2004; 45: 1311–1318.

    Article  CAS  PubMed  Google Scholar 

  51. Beran M, Wen S, Shen Y, Onida F, Jelinek J, Cortes J et al. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the MD Anderson Prognostic Scoring System. Leuk Lymphoma 2007; 48: 1150–1160.

    Article  PubMed  Google Scholar 

  52. Bain B, Vardiman JW, Imbert M, Pierre R . Myelodysplastic/myeloproliferative disease, unclassifiable. In Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumors: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001, pp 58–59.

    Google Scholar 

  53. Cannella L, Breccia M, Latagliata R, Frustaci A, Alimena G . Clinical and prognostic features of patients with myelodysplastic/myeloproliferative syndrome categorized as unclassified (MDS/MPD-U) by WHO classification. Leuk Res 2008; 32: 514–516.

    Article  PubMed  Google Scholar 

  54. Shaw GR . Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults. Br J Haematol 2005; 131: 180–184.

    PubMed  Google Scholar 

  55. Schmitt-Graeff A, Thiele J, Zuk I, Kvasnicka HM . Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity. Haematologica 2002; 87: 392–399.

    PubMed  Google Scholar 

  56. Nearman ZP, Szpurka H, Serio B, Warshawksy I, Theil K, Lichtin A et al. Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. Am J Hematol 2007; 82: 1076–1079.

    Article  CAS  PubMed  Google Scholar 

  57. Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006; 108: 1377–1380. E-pub 4 May 2006.

    Article  CAS  PubMed  Google Scholar 

  58. Atallah E, Nussenzveig R, Yin CC, Bueso-Ramos C, Tam C, Manshouri T et al. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of melodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. Leukemia 2008; e-pub ahead of print 6 December 2007; doi:10.1038/leu.2405054.

  59. Steensma DP, Caudill JS, Pardanani A, McClure RF, Lasho TL, Tefferi A . MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count. Haematologica 2006; 91 (12 Suppl): ECR57.

    PubMed  Google Scholar 

  60. Schmitt-Graeff AH, Teo SS, Olschewski M, Schaub F, Haxelmans S, Kirn A et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2008; 93: 34–40.

    Article  CAS  PubMed  Google Scholar 

  61. Zipperer E, Wulfert M, Germing U, Haas R, Gattermann N . MPL 515 and JAK2 mutation analysis in MDS presenting with a platelet count of more than 500 × 10(9)/l. Ann Hematol 2008; 87: 413–415; Letter.

    Article  CAS  PubMed  Google Scholar 

  62. Malcovati L, Cazzola M . Myelodysplastic/myeloproliferative disorders. Haematologica 2008; 93: 4–6.

    Article  PubMed  Google Scholar 

  63. Takahashi H, Furukawa T, Hashimoto S, Kanazawa N, Satoh N, Suzuki N et al. 5q-syndrome presenting chronic myeloproliferative disorders-like manifestation: a case report. Am J Hematol 2000; 64: 120–123.

    Article  CAS  PubMed  Google Scholar 

  64. Ingram W, Lea NC, Cervera J, Germing U, Fenaux P, Cassinat B et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia 2006; 20: 1319–1321. E-pub 2006 Apr 13.

    Article  CAS  PubMed  Google Scholar 

  65. Melchert M, Kale V, List A . The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. Curr Opin Hematol 2007; 14: 123–129. Review.

    Article  CAS  PubMed  Google Scholar 

  66. Horny HP, Sotlar K, Sperr WR, Valent P . Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 2004; 57: 604–608.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Professor James W Vardiman, University of Chicago, for his valuable advice, critical review and suggestions on how to improve the paper.

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Clarian Pathology Laboratory, Indiana University School of Medicine, Indianapolis, IN, USA

    A Orazi

  2. Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany

    U Germing

Authors
  1. A Orazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U Germing
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Orazi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Orazi, A., Germing, U. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 22, 1308–1319 (2008). https://doi.org/10.1038/leu.2008.119

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.119

Keywords

This article is cited by

Search

Advanced search

Quick links